A network meta-analysis of 22 RCTs of 2,258 participants found that lean mass accounted for roughly 25% of total weight lost on GLP-1 drugs, and DXA body-composition substudies report a range of 2640%
A 30-day follow-up found no significant changes in selected liver and kidney laboratory markers, but the group was small and the duration was insufficient to define long-term safety
Disclaimer: This information is for educational purposes only and not a substitute for medical advice
Tirzepatide works by mimicking hormones that: Delay stomach emptying Suppress hunger hormones Support insulin control The result
2maximum elevation of 1/4 of the tail length
This information may help explain why certain GLP-1 formulations or doses work better for some patients than others, though genetic data should complement, not replace, clinical evaluation